Skip to search formSkip to main contentSkip to account menu

nebicapone

Known as: 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
&NA;Catechol-O-methyltransferase (COMT) inhibitors are drugs commonly used in the management of patients with Parkinson disease… 
2011
2011
Objectives  Patients with Parkinson's disease can benefit from controlled released levodopa dosage forms since there is a clear… 
2010
2010
Abstract Objective: To investigate the chronopharmacology of nebicapone, a new catechol-O-methyltransferase (COMT) inhibitor… 
2010
2010
OBJECTIVE This study investigated the absorption, distribution, metabolism and excretion (ADME) of nebicapone [BIA 3-202; 1-(3,4… 
2008
2008
ObjectiveNebicapone is a new catechol-O-methyltransferase inhibitor. In vitro, nebicapone has showed an inhibitory effect upon… 
2008
2008
AbstractBackground and objectives: Levodopa is the most effective symptomatic treatment for Parkinson’s disease (PD), but its use… 
2007
2007
Nebicapone is a new nitrocatechol‐type inhibitor of Catechol‐O‐methyltransferase, developed for the treatment of Parkinson’s… 
2006
2006
Nebicapone (BIA 3-202; 1-[3,4-dihydroxy-5-nitrophenyl]-2-phenylethanone), a novel catechol-O-methyltransferase inhibitor, is…